Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$0.39.

  • Janux Therapeutics' EPS (Basic) rose 2352.94% to -$0.39 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.67, marking a year-over-year decrease of 4396.55%. This contributed to the annual value of -$1.28 for FY2024, which is 275.95% up from last year.
  • Janux Therapeutics' EPS (Basic) amounted to -$0.39 in Q3 2025, which was up 2352.94% from -$0.55 recorded in Q2 2025.
  • Janux Therapeutics' 5-year EPS (Basic) high stood at -$0.11 for Q2 2024, and its period low was -$2.06 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.39 (2025), whereas its average is -$0.46.
  • In the last 5 years, Janux Therapeutics' EPS (Basic) skyrocketed by 8446.6% in 2022 and then crashed by 40000.0% in 2025.
  • Over the past 5 years, Janux Therapeutics' EPS (Basic) (Quarter) stood at -$0.29 in 2021, then plummeted by 34.48% to -$0.39 in 2022, then surged by 38.46% to -$0.24 in 2023, then plummeted by 56.71% to -$0.38 in 2024, then fell by 3.7% to -$0.39 in 2025.
  • Its EPS (Basic) stands at -$0.39 for Q3 2025, versus -$0.55 for Q2 2025 and -$0.38 for Q1 2025.